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The first suggestion that prostaglandins (PG's)
may participate in the release of renin came from
Strong et al, who reported a large increase in renin
and PG contents in the ischemic half of a kidney
from a woman with renovascular hypertension [Ii.
Although we now know that tissue PG content is
not meaningful because PG's, unlike renin, are not
stored in tissues, the observation by Strong et al did
prompt researchers to look at the effect of PG's on
renin release.
Vander was the first to examine the effect of
PGE2 and PGE1 on renin release, but found that
these PG's were inactive in the dog [21. His conclu-
sions were that PG's could participate in renal
physiology, but probably not in the release of renin.
With the important discovery by Vane, that nonste-
roidal antiinflammatory drugs inhibit PG synthesis
[3], another approach could be taken to examine the
participation of PG's on renin release. Indeed,
indomethacin was found to lower plasma renin
activity in the dog, rabbit, and man [4—6]. This
effect of indomethacin on renin release was quick in
onset and unaffected by salt intake [71. The fact that
structurally dissimilar nonsteroidal antiinflamma-
tory drugs also lowered plasma renin activity added
credence to the idea that PG's may play an impor-
tant role in the release of renin. Further evidence
solidifying the interrelationship between PG's and
renin release was the demonstration that the infu-
sion of arachidonic acid (precursor of the PG's of
the "2" series) into the renal artery or the lower
aorta in the rabbit, rat, and dog resulted in an
increase in the plasma renin activity [5, 8, 9]. In
addition, arachidonic acid, when incubated with
rabbit renal cortical slices caused the release of
renin into the media. This effect of arachidonic acid
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was inhibited by the addition of indomethacin to the
media, demonstrating that arachidonic acid had to
be metabolized to a PG to be active [101.
Once the importance of PG's in the release of
renin was appreciated, two important questions
remained to be answered. Which of the known
intrinsic mechanisms of renin release is mediated by
the PG's, and which of the intrarenal PG's is
responsible for the release of renin?
There are essentially three intrinsic mechanisms
for renin release from the mammalian kidney (Fig.
1). The evidence for this recently has been reviewed
by Davis and Freeman [11]. The renal vascular
baroreceptor senses changes in either renal perfu-
sion pressure or vascular wall tension to alter renin
release, such that a decrease in perfusion pressure
increases renin release. The macula densa, located
at the distal end of the ascending limb of the loop of
Henle, senses alterations in the distal delivery of
sodium chloride to modulate renin secretion. A
decrease in the distal tubular delivery of sodium
chloride results in renin release, whereas an in-
crease in distal tubular delivery of sodium chloride
results in the inhibition of renin release. And the
sympathetic nervous system participates in the re-
lease of renin most likely through direct activation
of 3-adrenergic receptors in the juxtaglomerular
apparatus.
Under normal circumstances these three mecha-
nisms work in concert to release renin to various
stimuli. As an example, during hypotensive hemor-
rhage there is activation of the intrarenal barorecep-
tors through the decrease in renal perfusion pres-
sure to release renin. There is activation of the
macula densa because renal hypotension is associ-
ated with an increased proximal tubular reabsorp-
tion of sodium chloride, thereby decreasing distal
delivery, and systemic hypotension activates the
sympathetic nervous system via the carotid barore-
ceptors to release renin. The mediator for the
various mechanisms of renin release has not been
identified. For the sympathetic nervous system, the
presumed mediator of renin release is norepineph-
rifle. But, whether norepinephrine releases renin
through the interaction with 3-adrenergic receptors
or ct-adrenergic receptors is not clear. Because the
juxtaglomerular apparatus is innervated with sym-
pathetic nerves, the presumption has been that
sympathetic activation directly stimulates the juxta-
glomerular cells to secrete renin.
The mechanism by which intrarenal baroreceptor
activation and macula densa activation results in
renin release is even less understood. But, because
PG inhibitors lower basal renin secretion, and ara-
chidonic acid stimulates renin release, we were
curious to see whether any of the intrinsic mecha-
nisms for renin release were mediated by PG's.
There were more than theoretical reasons to believe
that PG's could play an integral role in renin re-
lease. It had been reported that both the hemody-
namic changes and renin secretory effects of furose-
mide could be totally inhibited by PG synthesis
inhibitors. Because according to Corsini, Hook,
and Bailie furosemide could release renin through
either the activation of the intrarenal baroreceptor
or the macula densa mechanism [121, we decided to
examine first the baroreceptor mechanism of renin
release as it relates to the PG system.
The study was performed in mongrel dogs [41.
The sympathetic influences on renin release were
excluded by renal sympathectomy, adrenalectomy,
and the administration of f3-adrenergic blocking
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Fig. 2. Effect of activation of the renal baroreceptors by aortic
clamping above the renal arteries on renal venous plasma renin
activity. Clear bars represent the control dogs, and the hatched
bars represent the dogs treated with indomethacin. All the
kidneys were nonfiltering, denervated, and 3-adrenergically
blocked to isolate the renal baroreceptors. Values are the means
SEM. Asterisks denote P < 0.05.
doses of propranolol. The macula densa mechanism
of renin release was excluded by rendering the
kidneys of these animals nonfiltering by the method
of Blame, Davis, and Prewitt [13]. Thus, the only
remaining mechanism of renin release in these
animals was by stimulation of the intrarenal barnre-
ceptors. First, we established that in this prepara-
tion intrarenal infusion of arachidonic acid pro-
duced renin release. This assured us that our prepa-
ration was still responsive to enhanced PG
synthesis. The intrarenal baroreceptor was then
activated by decreasing renal perfusion pressure by
50% with an aortic clamp placed above the renal
arteries. This procedure was performed in the ab-
sence and the presence of indomethacin. We con-
sistently observed several-fold increases in renal
venous plasma renin activity after 50% reduction in
perfusion pressure in the control animals, an effect
that was totally abolished by indomethacin (Fig. 2).
Thus, it appeared that at least the renal barorecep-
tor-mediated increase in renin release was PG de-
pendent.
To examine the relationship of the macula-densa-
stimulated renin release and PG synthesis, we used
a slightly different preparation in mongrel dogs. To
remove sympathetic influences, we denervated the
kidneys and we treated the animals with -adrener-
gic blocking doses of propranolol. To inactivate the
intrarenal baroreceptors, we gave the animals a
constant intrarenal infusion of papaverine. Papaver-
me by itself does not cause renin release but will
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Fig. 1. Schematic representation of the three intrinsic mecha-
nisms of renin release: the renal baroreceptor in the afferent
arteriole, sympathetic nerves, and the macu/a densa located in
the distal tubule.
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Table 1. Effect of prostaglandin inhibition (group II) and lack of renal tubular fluid flow (group III) on the macula-densa-stimulated
renin releas&'
Arterial PRA, ng Al/mi/hr
—20 mm —5 mm
Clamp
10 mm 25 mm
Group I
Group II
Group III
2.7 0.6
1.0 0.5
1.4 0.3
2.8 0.6
0.8 0.5
1.5 0.5
5.6 0.8k'
1.8 0.9
1.4 0.4
6.6 09b
1.5 0.8
2.0 0.4
a Group I is denervated, propranolol-treated, papavarine-infused, filtering kidney. Group II is the same as group I, except it was
treated with cyclooxygenase inhibitor. Group III is the same as group I except the kidneys were nonfiltering. In this preparation,
intrarenal papaverine paralyzed the renal baroreceptors, and renal denervation and propranolol administration inactivated the
adrenergic-mediated renin release, thereby functionally isolating the macula densa mechanism of renin release. Aortic clamping above
the renal arteries stimulated the macula densa mechanism of renin release by decreasing the distal tubular delivery of sodium chloride
(group I). If the dogs were pretreated with a cyclooxygenase inhibitor, the expected rise in renin release to aortic clamping was blocked
(group II), demonstrating that prostaglandin synthesis was necessary for renin release. In addition, tubular fluid flow was necessary to
observe the rise in renin to aortic clamping (group III), thus demonstrating that the macula densa mechanism of renin release was indeed
isolated in this preparation. Values are the means SEM.b p < 0.05.
inhibit the baroreceptor-stimulated renin release in
the dog [141. The macula densa mechanism of renin
release was stimulated by reducing renal perfusion
pressure by 50% with a suprarenal aortic clamp
[15]. This maneuver decreased the urinary excre-
tion of sodium to less than 10% of the basal value,
indicating an increased proximal tubular sodium
reabsorption and a decreased distal tubular sodium
delivery. The macula densa mechanism of renin
release was stimulated in the absence and the
presence of a cyclooxygenase inhibitor (indometh-
acm or meclofenamic acid). Aortic clamping in-
creased arterial plasma renin activity 2.5-fold in the
animals not receiving a cyclooxygenase inhibitor,
but plasma renin activity remained unchanged in
the animals with cyclooxygenase inhibitors present
(Table 1). To assure that in this preparation, the
activation of the intrarenal baroreceptor was not the
responsible stimulus for the release of renin, we
repeated these experiments in dogs with nonfilter-
ing kidneys. In six dogs with a single nonfiltering
kidney, aortic clamping above the renal artery did
not stimulate renin release when the animals were
receiving intrarenal papaverine. This control pro-
vided us with the necessary information to conclude
that intact tubular function was necessary to stimu-
late the renin release in this preparation. Thus, both
the macula densa and the baroreceptor-mediated
renin release require PG synthesis.
The interaction between sympathetic nervous
system and renin release is more complicated.
When the sympathetic nervous system is activated,
there is an end-organ interaction at both a- and 13-
adrenergic receptors. A study by Berl et al [161, in
dogs, very clearly demonstrated that the 3-adrener-
gic mechanism of renin release is independent of the
PG system. But, the natural neurotransmitter of the
sympathetic nervous system, norepinephrine, inter-
acts with both a and 3-adrenergic receptors. Al-
though in vitro a-adrenergic receptors may be in-
hibitory to renin release, in vivo stimulation of
vascular a-adrenergic receptors has been suggested
to release renin [171. Alpha-adrenergically mediated
renin release might be due to the generation of a
vasodilatory PG, which could counteract vasocon-
striction and release renin, or it could be due to
decreased delivery of sodium chloride to the macula
densa with stimulation of renin release through a
tubular mechanism. In either event, PG's ought to
be the mediator of the renin release. To establish
whether a-adrenergic receptors participate in the
release of renin, we infused phenylephrine into one
of the renal arteries of mongrel dogs at three
different doses chosen to decrease renal blood flow
15, 30, and 50% of the basal value, and we mea-
sured renin secretory rate and urinary excretion of
sodium. In all the animals, phenylephrine increased
renin secretory rate. This increase in renin release
from phenylephrine infusion was severely attenuat-
ed in the animals treated with 8 mg/kg of indometh-
acm. Because in these animals there was a decrease
in both renal blood flow and urinary excretion of
sodium, the mechanism of renin release could have
been through the renal baroreceptor or macula
densa mechanism. To elucidate the mechanism
further, we infused phenylephrine into the renal
artery of dogs with one nonfiltering kidney, in
which the macula densa mechanism of renin release
was inactivated. In these animals, phenylephrine
did not stimulate renin release, suggesting that the
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a-adrenergic stimulated renin release resulted from
activation of the macula densa.
Thus, from our data, we could conclude that PG's
participate in the baroreceptor, macula densa, and
the a-adrenergic-mediated renin release. Thus, only
the -adrenergic mechanism of renin release is
independent of the PG system. This schema agrees
with the data by Frölich et al that the isoproterenol
induced renin release in people is independent of
the PG system, and that propranolol and indometh-
acm given together abolishes the renin response to a
low sodium diet and upright posture [7].
Now that the critical role for PG's in the release
of renin was established, the question as to which of
the renal PG's is responsible for renin release
remained. But, the answer to this question is not
simple. The literature is filled with inconsistencies,
so that no conclusive statement can be made about
the effect of any one PG. Prostaglandin '2(prostacy-
din) appears to be a leading candidate because in
vitro it is three times more potent than PGE2 in
releasing renin from rabbit renal cortical slices, and
rabbit cortical microsomes have the capacity to
make PGI2 [18, 19]. But, the effect of exogenously
administered PG!2 or the other PG's on renin re-
lease in vivo is difficult to interpret because all the
vasodilatory PG's cause a natriuresis, and PGE2
has a potent effect to inhibit sympathetic neuro-
transmitter release. Thus, the best model to exam-
ine the effect of PG's on renin release in vivo is the
dog with a nonflitering, indomethacin-treated and
3-adrenergical1y blocked kidney. Using this model,
we found that PG!2 was indeed slightly more potent
than PGE2 in causing renin release [201. But, a
metabolite of PGE2, 13,14-dihydro PGE2 was even
more potent in releasing renin than was either PGE2
or PG!2. Because PGE2 is subject to fairly rapid
metabolism by the kidney whereas dihydro PGE2
and PGI2 are not, and because the intrinsic potency
of PGE2 and dihydro PGE2 is about even in in vitro
systems where no metabolism occurs [21], it is
likely that the intrinsic potency of PGE2 to release
renin is as high as that of PG12 in the dog, but rapid
metabolism of PGE2 prevents the full expression of
its potency (Fig. 3).
In the rabbit, PGI2 may be more potent than
PGE2 in releasing renin as witnessed by the in vitro
cortical slice experiments. But, there may be spe-
cies differences, and because full measurements of
the various PG's produced by the kidneys during
stimulation of renin release have not been done,
both PG!2 and PGE2 remain as potential mediators
of renin release. Prostaglandin D2 in our hands did
not stimulate renin release in indomethacin- and
propranolol-treated dogs, even though it was a
potent renal vasodilator [221. In addition, in rabbit
renal cortical slices, PGD2 was reported to be
inactive in releasing renin [19]. Thromboxane A2, a
vasoconstrictor, would be a poor candidate to cause
renin release on its own because it tends to decrease
cyclic AMP in tissues, but the stimulators of renin
release, like isoproterenol, PGI2, and PGE2 tend to
increase cyclic AMP levels in tissues. Because
dibutyryl cAMP itself increases renin release in
vivo, the second messenger to renin release may
very well be cyclic AMP [23]. in addition, the cyclic
ether endoperoxide analogue, which mimics many
of the effects of thromboxane A2 in tissues, does not
stimulate renin release in animals pretreated with
indomethacin [24].
Clinical significance of prostaglandin and renin
release
The importance of renal PG' s in human patho-
physiology came to be appreciated when reports of
the therapeutic effect of nonsteroidal antiinfiamma-
tory drugs in the treatment of Bartter's syndrome
were published [25]. Although the physiologic un-
derstanding of the syndrome is far from complete,
100
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Fig. 3. Effect of intrarenal infusion of increasing doses of PGI2,
PGE2, and 13,14-dihydro-PGE2 on renin secretory rate in dogs
with a single nonfiltering, denerva ted, and 13.adrenergic blocked
kidney. Values are the means SaM. Asterisks denote P < 0.05.
C is control. Amounts of doses were measured in nanograms per
kilogram per minute.
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overproduction of renal PG's is a fairly uniform
feature. All of these patients are hyperreninemic,
have renal tubular sodium wasting, and have hypo-
tension with resistance to pressor agents like angio-
tensin II. The use of indomethacin will improve
many of these features, suggesting that overproduc-
tion of a PG is responsible for many of the features
of Bartter's syndrome. Whether this PG overpro-
duction is a primary or a secondary phenomenon is
not clear. In these patients, the renal excretion of
PGE2 is elevated several-fold above normal, and
consequently it was initially thought that overpro-
duction of PGE2 was responsible for the hyperren-
inemic state [25]. But, since that time, Güllner,
Smith, and Bartter reported that urinary excretion
of 6-keto PGF1a is elevated as well [261, and some
of the features of Bartter's syndrome are more
compatible with a circulating PG rather than a local
PG. Because PGI2 is not extracted by the lung,
whereas PGE2 is avidly extracted [27], PGI2 could
circulate and be responsible for the peripheral mani-
festations of Bartter's syndrome like the vascular
insensitivity to angiotensin II. In addition, patients
with Bartter's syndrome have a platelet defect that
is correctable with the use of indomethacin [281,
favoring an elevated circulating PGI2 rather than
PGE2.
Hypertension may be another disease where re-
nal PG's could play a role in elevating plasma renin
activity. Although this possibility has not been
extensively explored in man, a recent report in
abstract form has suggested that in rats, the rise in
blood pressure after aortic ligation between the
renal arteries can be attenuated by the use of
indomethacin [291. In these animals there was a
correlation between the lowering of blood pressure
and lowering of plasma renin activity. The possibili-
ty that some forms of hyperreninemic hypertension
in man are prostaglandin mediated would open up a
whole new role for the nonsteroidal antiinflamma-
tory drugs as antihypertensive therapeutic agents,
although the potential dangers of inhibition of PG
synthesis in patients with compromised renal func-
tion would have to be carefully evaluated.
Summary. We have provided evidence that the
renal PG's intimately participate in the release of
renin. Prostaglandins are the sole mediators of renin
release secondary to the stimulation of the renal
baroreceptors and the macula densa. In addition,
stimulation of a-adrenergic receptors result in PG-
mediated renin release via the activation of the
macula densa. The 3-adrenergic mechanism of re-
nm release is independent of the PG system. Of the
PG's produced by the renal cortex, only PGI2 and
PGE2 are active in releasing renin both in vitro and
in vivo. Although PGI2 is a more attractive candi-
date than PGE2 as a mediator of the release of
renin, because it is produced by the vascular endo-
thelium, which is in direct proximity to the juxtaglo-
merular apparatus, the present evidence cannot
incriminate one PG over the other as the mediator.
The knowledge that PG's participate in the release
of renin has enhanced our understanding of clinical
entities like Bartter's syndrome and hypertension.
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